Nephrotic syndrome co-existing with type 1 diabetes in a 12-year-old boy: Case report and literature review

Noor S Bawahab1, Osama Y Safdar2, Sarah A Nagadi1, Asalh T Saeedi1 and Raghad W Mohammed Hussain1

Abstract
Occurrence of early nephrotic syndrome in type 1 diabetes mellitus patients is extremely rare. Herein, we report the case of a 12-year-old boy who presented to our pediatric nephrology clinic with generalized edema. He had been diagnosed with type 1 diabetes mellitus at age 9 and had been treated with regular insulin. Examinations revealed normal kidney function, hypoalbuminemia, proteinuria (4+), hyperlipidemia, and low protein-to-creatinine ratio. The patient was diagnosed with idiopathic nephrotic syndrome and was empirically administered prednisolone for 12 weeks. Subsequently, prednisolone was tapered over 10–12 weeks. The patient showed good response to treatment. In conclusion, co-existence of nephrotic syndrome and type 1 diabetes mellitus may suggest an immunological basis; therefore, further studies are needed to investigate the relationship between these two conditions.

Keywords
Nephrotic syndrome, type 1 diabetes, edema, prednisolone

Date received: 19 June 2018; accepted: 10 January 2019

Introduction
Nephrotic syndrome is a common childhood disease characterized by massive proteinuria, hypoalbuminemia, hyperlipidemia, and edema.1,2 Notably, it exhibits a variety of patterns on histopathology analysis, such as minimal change disease (MCD), focal segmental glomerulonephritis, and membranoproliferative glomerulonephritis; MCD comprises the most common pattern in children.3,4 Clinicians are often cautious when differentiating between nephrotic syndrome in a diabetic patient and diabetic nephropathy. Importantly, diabetic nephropathy is associated with long-term diabetes (>10 years) and a certain pattern of reduced renal function.5 The occurrence of nephrotic syndrome and type 1 diabetes mellitus (T1DM) is extremely rare.6 Herein, we report the case of a 12-year-old boy with T1DM who developed early-onset nephrotic syndrome.

Case
A 12-year-old Caucasian boy presented to the pediatric nephrology clinic with generalized edema that had originated periorbitally and then progressed to cover his entire body. He had been diagnosed with T1DM (1A) at the age of 9 and had been treated with insulin 1 U/kg/day, administered as short-acting insulin before each meal three times per day, combined with long-acting insulin glargine once per day. The patient reported a healthy diet and a habit of exercise. His HbA1C level was between 5% and 5.6% and he had not developed any diabetic complications, such as retinopathy and neuropathy. There was no family history of edema. His weight was 35 kg (25th percentile), height was 145 cm (25th percentile), and body mass index (BMI) was 16.6 kg/m² (25th percentile).

Laboratory investigations revealed normal kidney function, hypoalbuminemia, proteinuria (4+), hyperlipidemia, protein-to-creatinine ratio of 3.5, normal thyroid function, and negative celiac screen. The laboratory results are shown in Table 1. The patient was diagnosed with idiopathic nephrotic syndrome and was empirically administered prednisolone for 12 weeks. Subsequently, prednisolone was tapered over 10–12 weeks. The patient showed good response to treatment. In conclusion, co-existence of nephrotic syndrome and type 1 diabetes mellitus may suggest an immunological basis; therefore, further studies are needed to investigate the relationship between these two conditions.

Keywords
Nephrotic syndrome, type 1 diabetes, edema, prednisolone

Date received: 19 June 2018; accepted: 10 January 2019
nephrotic syndrome and treated empirically with prednisolone (60 mg/m² for 6 weeks, followed by 40 mg/m² for an additional 6 weeks) with “sliding scale” insulin therapy. Prednisolone was then tapered over 10–12 weeks. Blood glucose levels were strictly controlled. The patient’s symptoms improved, and proteinuria disappeared within 12 days after initiating steroid treatment.

Discussion

The incidence of nephrotic syndrome in children in the United States and Europe is 1–7 per 100,000 children. Patients with T1DM present with proteinuria (diabetic nephropathy) at a late stage, approximately 12 years after the onset of diabetes. A short period of T1DM and the absence of target organ damage (e.g. retinopathy)—as in our case—suggest the existence of a non-diabetic nephropathy and emphasize the importance of renal biopsy. Early diabetic nephropathy is detected by an increased glomerular filtration rate, which is related to increased cell growth and expansion in the kidneys that may be induced by hyperglycemia. Microalbuminuria typically occurs 5 years after the onset of T1DM. Moreover, nephropathy with proteinuria (>300 mg/day) often develops 10–15 years after the onset of T1DM. End-stage renal failure develops in 50% of patients within 10 years of the onset of T1DM.

Although the association between nephrotic syndrome and T1DM is rare, there is some evidence to support an immunological basis in multiple patients. The underlying etiology of this relationship is unknown. Notable examples include the following: a 3-year-old boy was simultaneously diagnosed with T1DM and nephrotic syndrome; he exhibited positivity for human leukocyte antigen (HLA) A24, DR4, and DR53 antigens. Another report described the presence of DR4 in a 4-year-old boy with T1DM who developed nephrotic syndrome. T1DM and steroid-sensitive nephrotic syndrome may share HLA loci that carry a genetic predisposition to both diseases. Importantly, previous studies have revealed an HLA-related association among autoimmune diseases, including celiac disease, autoimmune thyroiditis, autoimmune hepatitis, and T1DM with nephrotic syndrome. A notable example was a 35-year-old man who was referred to the nephrology clinic for treatment of edema; he had an 18-year history of T1DM and a 6-year history of Hashimoto’s thyroiditis. In that patient, a relationship was reported among T1DM, Hashimoto’s thyroiditis, and MCD. Furthermore, thyroiditis and diabetes-associated autoantibodies were present in a young girl with T1DM who developed icterus, which was caused by autoimmune hepatitis; HLA typing revealed DRB1*03 heterozygosity, associated with both autoimmune hepatitis and T1DM.

To further highlight the association between nephrotic syndrome and T1DM, we note the case of a 19-year-old female with a 4-year history of T1DM, who had been treated with insulin and aspirin of 100 mg/day; she reported the occurrence of facial and bilateral limb edema for the prior 1 month. She reported no arthralgia and had a history of an uneventful pregnancy with a stillborn child, 8 months prior. Physical examination revealed pitting edema on the legs and face; urinalysis showed proteinuria of 5.3 g/24 h, and renal biopsy findings indicated MCD.

In addition, Urizar et al. reported five cases of patients who were diagnosed with T1DM and developed manifestations of nephrotic syndrome, such as generalized edema, proteinuria, hypoproteinemia, and hypercholesterolemia. These cases were managed by administration of insulin, steroid, or both; the dose of insulin was increased to normalize hyperglycemia caused by steroid intake, as in our case. Moreover, Robinson et al. described a patient with uncontrolled diabetes during administration of steroid therapy; thus, the dose of insulin was increased. Regarding the outcome of nephrotic syndrome, our patient showed a dramatic response to treatment with complete remission. In contrast,

| Lab test                                      | Results       | Normal range            | Last follow-up |
|----------------------------------------------|---------------|-------------------------|----------------|
| Creatinine                                   | 40 µmol/L     | 30–50 µmol/L            | 42 µmol/L      |
| Albumin                                      | 20 g/L        | 53–45 g/L               | 41 g/L         |
| Cholesterol                                  | 7 mmol/L      | 60–300 mmol/L           | 3.2 mmol/L     |
| Protein-to-creatinine ratio                  | 3.5 mg/mg     | <5.2 mmol/L             | 3.0 mmol/L     |
| Thyroid function test                        | T4 15 pmol/L  | T4 11–21 pmol/L         |               |
|                                              | T3 4 pmol/L   | T3 3–6 pmol/L           |               |
|                                              | TSH 2 mU/L    | TSH 0.5–5 mU/L          |               |
| Celiac screen test (tissue transglutaminase  | 1 U/mL (negative) | <4 U/mL                |               |
| C-peptide                                    | 112 pmol/L (low) | 300–1300 pmol/L        |               |
| Anti-islet cell autoantibody                 | Positive      | Negative                |               |
| Antibodies to glutamic acid decarboxylase    | 8 U/mL (elevated) | <0.7 U/mL              |               |
| Anti-insulin antibody                        | 12 U/L        | <1 U/L                  |               |
| HLA                                          | Not done      | Not done                |               |

T4: thyroxine; T3: triiodothyronine; TSH: thyroid-stimulating hormone; HLA: human leukocyte antigen.
two prior patients exhibited relapse and recurrence. A summary of the above cases is shown in Table 2.

**Conclusion**

Co-existence of nephrotic syndrome and T1DM may suggest an immunological basis for the relationship between these diseases; further studies are needed to explore the underlying etiology.

**Acknowledgements**

The authors would like to thank Dr Turki Alahamdi, Pediatric Chairman, for his support and helping in reviewing the manuscript.

**Declaration of conflict of interests**

The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

**Ethics approval**

Ethical approval to report this case series was obtained from Institutional Ethics Committee, King Abdulaziz University Hospital, Jeddah, Saudi Arabia.

**Funding**

The author(s) received no financial support for the research, authorship, and/or publication of this article.

**Informed consent**

Written informed consent was obtained from a legally authorized representative for anonymized patient information to be published in this article.

**ORCID iD**

Noor S Bawahab [https://orcid.org/0000-0002-4735-7184](https://orcid.org/0000-0002-4735-7184)

---

**Table 2. Summary of prior reports of nephrotic syndrome associated with early-onset type 1 diabetes mellitus in pediatric patients.**

| References            | Age at onset of diabetes (years) | Age at onset of nephrotic syndrome (years) | Proteinuria level (g/24 h) | Treatment          | Outcome            |
|-----------------------|----------------------------------|--------------------------------------------|----------------------------|--------------------|--------------------|
| Urizar et al.17       | 4                                | 4 (1 week after DM1)                       | 3.4                        | Insulin            | Resolved completely|
| Urizar et al.17       | 8                                | 8                                          | 7.2                        | Steroid            | Resolved completely|
| Urizar et al.17       | 3                                | 4                                          | 14                         | Steroid            | Resolved completely|
| Urizar et al.17       | 5                                | 5                                          | 17                         | Steroid            | Recurrence         |
| Urizar et al.17       | 2 months                         | 10                                         | 7.3                        | Steroid            | Recurrence         |
| Robinson et al.18     | 3                                | 3 (2 months after DM1)                     | –                          | Steroid            | Resolved completely|
| Agras et al.13        | 3                                | 3 (10 months after DM1)                    | –                          | Steroid            | Relapsed           |
| Otukesh and Torabi6   | Infancy                          | 5                                          | –                          | Steroid            | Recurrence         |
| Rego Filho et al.14   | 3                                | 3                                          | 0.529                      | Steroid–cyclophosphamide | Relapsed           |
| Dizdar et al.15       | 17                               | 35                                         | 3.7g/day                   | Cyclophosphamide   | Resolved completely|
| Moyses Neto et al.10  | 15                               | 19                                         | 5.3g/24h                   | Steroid            | Resolved completely|

**References**

1. Srivastava RN. 50 years of nephrotic syndrome in children, and hereafter. *Indian Pediatr* 2013; 50: 107–110.
2. Safaei AA and Maleknejad S. Clinical and laboratory findings and therapeutic responses in children with nephrotic syndrome. *Indian J Nephrol* 2010; 20: 68–71.
3. Obiagwu PN, Aliyu A and Atanda AT. Nephrotic syndrome among children in Kano: a clinicopathological study. *Niger J Clin Pract* 2014; 17: 370–374.
4. de Seigneux S and Martin PY. Management of patients with nephrotic syndrome. *Swiss Med Wkly* 2009; 139: 416–422.
5. Kveder R, Kajtna-Koselj M, Rott T, et al. Nephrotic syndrome in patients with diabetes mellitus is not always associated with diabetic nephropathy. *Nephrol Dial Transpl* 2001; 16: 68–71.
6. Otukesh H and Torabi A. Co-existence of type I diabetes mellitus and nephrotic syndrome with membranous glomerulonephritis in a 6-year old boy: report of a case. *Int J Child Adolesc* 2016; 2: 25–27.
7. International Study of Kidney Disease in Children. Nephrotic syndrome in children: prediction of histopathology from clinical and laboratory characteristics at time of diagnosis. *Kidney Int* 1978; 13: 159–165.
8. McKinney PA, Feltbower RG, Brocklebank JT, et al. Time trends and ethnic patterns of childhood nephrotic syndrome in Yorkshire, UK. *Pediatr Nephrol* 2001; 16: 1040–1044.
9. Niaudet P. Steroid-sensitive nephrotic syndrome in children. In: Avner ED, Harmon WE and Neasden P (eds) *Paediatric nephrology*. Philadelphia, PA: Lippincott Williams and Wilkins, 2004, pp. 543–556.
10. Moyses Neto M, Silva GE, Costa RS, et al. Minimal change disease associated with type 1 and type 2 diabetes mellitus. *Arg Bras Endocrinol* 2012; 56: 331–335.
11. Kari JA, El-Desoky SM, Mokhtar G, et al. Simultaneous onset of steroid resistant nephrotic syndrome and IDDM in two young children. *BMJ Case Rep* 2010; 2010: bcr0420102916.
12. Hall P. Prevention of progression in diabetic nephropathy. *Diabetes Spectr* 2006; 19: 18–24.
13. Agras PI, Kinik ST, Cengiz N, et al. Type 1 diabetes mellitus associated with nephrotic syndrome. *J Pediatr Endocrinol* 2006; 19: 1045–1048.

14. Rego Filho EA, Mello SF, Omuro AM, et al. Simultaneous onset of steroid-sensitive nephrotic syndrome and type 1 diabetes. *J Pediatr* 2003; 79: 557–560.

15. Dizdar O, Kahraman S, Gençtoy G, et al. Membranoproliferative glomerulonephritis associated with type 1 diabetes mellitus and Hashimoto’s thyroiditis. *Nephrol Dial Transpl* 2004; 19: 988–989.

16. Hovinga IC, Stam ED, Mearin ML, et al. A girl with type 1 diabetes and a yellowish appearance. *BMJ Case Rep* 2010; 2010: bcr0420102899.

17. Urizar RE, Schwartz A, Top F Jr, et al. The nephrotic syndrome in children with diabetes mellitus of recent onset. *New Engl J Med* 1969; 281: 173–181.

18. Robinson LA, Howell DN, Wigfall DR, et al. Appearance of immune complex glomerulonephritis following the onset of type I diabetes mellitus in a child. *Am J Kidney Dis* 1997; 30: 713–716.